Screener
CareDx CDNA G&A
G&A at other companies
Other financials
Where this comes from
Reported directly by CareDx in its filing.
Tagged under the XBRL concept us-gaap:GeneralAndAdministrativeExpense.
The source filing: CareDx’s 10-Q, filed April 28, 2026.
- Filed
- Apr 28, 2026, 4:13 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001217234-26-000033
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Cost of patient and digital solutions | 11,698 | 7,716 |
| Research and development | 21,416 | 18,524 |
| Sales and marketing | 30,373 | 22,991 |
| General and administrative | 30,484 | 22,769 |
| Litigation settlement expense | 600 | 5,360 |
| Total operating expenses | 116,502 | 98,059 |
| Income (loss) from operations | 1,198 | (13,374) |
| Other income: |
ITEM 1. UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
FAQ
- What is CareDx's G&A?
- CareDx (CDNA) reported G&A of $30.48M in Q1 2026.
- How has CareDx's G&A changed year-over-year?
- CareDx's G&A increased by 33.9% year-over-year, from $22.77M to $30.48M.
- What is the long-term trend for CareDx's G&A?
- Over 4 years (2021 to 2025), CareDx's G&A has grown at a 9.4% compound annual growth rate (CAGR), from $74.96M to $107.57M.
- What does G&A mean?
- Overhead costs not directly tied to production or sales — corporate management, legal, accounting, office rent, insurance, and other administrative functions.
Ask your AI about CareDx's g&a.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude